BioLife Solutions vs Envista
Envista reported revenue of $2.7 billion in fiscal 2025, 28.3 times BioLife Solutions' $96 million in fiscal 2025. BioLife Solutions' revenue grew 28.9% in its latest year, and Envista's grew 8.3%. BioLife Solutions had an operating margin of -17.3%, against 8.0% at Envista. Free cash flow was $11 million at BioLife Solutions and $230 million at Envista.
Side by side
| BioLife Solutions | Envista | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $96M | $2.7B |
| Revenue growth | 28.9% | 8.3% |
| Revenue growth a year, last 5 years | 14.9% | 7.1% |
| Gross margin | 64.6% | 54.7% |
| Operating margin | −17.3% | 8.0% |
| Net margin | −4.8% | 1.7% |
| Free cash flow | $11M | $230M |
| Free cash flow margin | 11.1% | 8.5% |
| Return on capital | −4.8% | 3.2% |
| Net debt to EBITDA | — | 0.7x |
| Dividends and buybacks | $0M | $167M |
| Change in diluted share count | 5.6% | −1.7% |
| Last close | — | $23.66 |
| P/E at the last close | — | 40.8× |
| Insider trades, last 12 months | sold $34.0 million | sold $510,250 |
| Piotroski F-score | 6 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BioLife SolutionsEnvista
Operating margin
Percent of revenue
BioLife SolutionsEnvista
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioLife SolutionsEnvista
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioLife Solutions and Envista pages.